Join us for an in-depth and thought-provoking episode featuring Alan White, CEO and Co-founder of Arriello, as we explore the evolving world of global regulatory affairs, pharmacovigilance, quality, and compliance—and the powerful intersection of technology and human expertise that is redefining life sciences.

In this conversation, Alan shares his unconventional journey from a commercial career spanning IT, lighting, and translation services into the highly regulated pharmaceutical sector. He reflects on how early exposure to regulatory-driven services inspired him to found Arriello in 2008, during one of the most challenging global financial climates. From building credibility as a new entrant in a trust-based industry to scaling operations across continents, Alan offers a candid look at what it takes to transform a startup into a global organization supporting clients in more than 140 markets.

We dive into Arriello’s evolution from post-marketing regulatory support into a comprehensive strategic advisory partner spanning clinical development, drug safety, and compliance services. Alan unpacks the realities of navigating fragmented global regulatory systems, the importance of local expertise in global market entry, and the common mistakes biotech companies make when expanding internationally. The discussion also explores the growing role of AI and automation in compliance workflows—and why a human-in-the-loop approach remains essential to ensure accuracy, accountability, and sound judgment.

Episode Highlights:
A deep dive into the inspiration and early challenges behind founding Arriello
Insights into building credibility and trust in global regulatory consulting
The transformation from post-marketing support to full-spectrum strategic advisory services
Practical perspectives on integrating AI and automation while preserving human oversight
A forward-looking vision where regulatory affairs and pharmacovigilance become innovation drivers through digital transformation

Whether you're a biotech founder, regulatory professional, or life sciences executive, this episode offers strategic clarity on how compliance, technology, and leadership intersect in today’s global pharmaceutical landscape. Discover how combining digital capability with human expertise is shaping the future of regulatory excellence and accelerating innovation across life sciences.

Join us for an inspiring episode of Lab Bench to Boardroom: Leading Science-Driven Innovation featuring Ashley Zehnder, CEO of Fauna Bio, as we explore the intersection of bold scientific thinking, biotech leadership, and nature-inspired therapeutics. In this conversation, Ashley shares how Fauna Bio is redefining drug discovery by leveraging multi-omics insights from hibernating species to tackle some of the most complex human diseases.

Ashley reflects on her journey from veterinary science to leading a cutting-edge biotech company, offering candid insights into the challenges and opportunities of women in science and executive leadership. She recounts the founding story of Fauna Bio—sparked by a powerful realization that nature has already solved many biological challenges humans face—and how that “aha” moment evolved into a platform built on evolutionary biology and translational science.

We dive into how Fauna Bio integrates genomics, transcriptomics, and proteomics to uncover protective mechanisms embedded in hibernation biology, and how those insights are translated into potential therapeutics. Ashley also discusses the scientific and operational complexities of working with non-traditional model species, building a science-first culture, and scaling innovation while staying grounded in rigorous data.

Episode Highlights:
A deep exploration of women’s leadership and representation in biotech
Ashley Zehnder’s path from veterinary medicine to biotech CEO
The origin story and vision behind Fauna Bio
How hibernation biology can unlock transformative treatments in human health
Real-world examples of translating animal biology into therapeutic pipelines
Leadership lessons from building and scaling a mission-driven biotech company

Whether you're a scientist, entrepreneur, investor, or innovation leader, this episode offers a compelling look at how evolutionary biology and multi-omics technologies are converging to reshape drug discovery. Discover how science drawn from nature—combined with visionary leadership—can drive the next generation of breakthrough therapeutics.

Join us for a powerful and timely episode featuring Golda Naana Boakye, CEO of Naantu, as we examine the urgent need to advance diversity, equity, and inclusion in clinical research. In this compelling conversation, Golda shares why representative clinical trials are not only a matter of social responsibility, but a scientific and clinical imperative essential to improving outcomes for all patients.

We explore the systemic and structural barriers that continue to limit participation from underrepresented communities, from historical mistrust and access challenges to trial design limitations that fail to reflect real-world populations. Golda discusses the importance of rebuilding trust through transparency, meaningful community engagement, and culturally competent communication—shifting clinical research from a transactional model to a patient-centered partnership.

The conversation also highlights how innovative, technology-enabled approaches are helping to remove logistical barriers, expand access, and enhance the participant experience. From decentralized trial models to data-driven outreach strategies, we examine how sponsors and CROs can move beyond intention and toward measurable action in equity-driven research.

Episode Highlights:
A deep dive into why diversity in clinical trials strengthens scientific validity and patient outcomes
Key structural barriers preventing broader participation—and how to address them
The critical role of trust, transparency, and community engagement in recruitment
How digital tools and decentralized models can improve accessibility and inclusivity
Golda’s leadership journey and the mission driving Naantu
Practical strategies for sponsors and research organizations to build more representative trials
A forward-looking vision for patient-centric, equitable clinical research

Whether you're a biopharma executive, clinical researcher, sponsor, or healthcare innovator, this episode offers strategic clarity and actionable insights on building trials that truly reflect the populations they aim to serve. Discover how inclusive research design is shaping the future of medicine—and why equity must be embedded at the core of scientific progress.

Join us for a strategic and deeply insightful episode featuring Ramani Varanasi, Founder and CEO of ReVive Advisors, as we explore the leadership mindset, capital strategy, and decision-making discipline required to build and scale successful biopharma companies. Drawing from his journey from bench scientist to executive leader, entrepreneur, and trusted board advisor, Ramani shares practical lessons shaped by decades of navigating high-stakes environments in biotech.

In this conversation, Ramani reflects on the pivotal moments that shaped his transition into leadership and company-building, offering candid perspectives on balancing bold scientific vision with operational pragmatism. We examine how strong leaders make informed decisions amid uncertainty—particularly during critical clinical, regulatory, and financial inflection points where data may be incomplete and timelines unforgiving.

The discussion dives into patterns Ramani has observed across high-performing biopharma organizations, from aligning scientific ambition with investor expectations to building leadership teams capable of disciplined execution. He shares frameworks for evaluating risk, structuring capital strategy, and making difficult calls when the stakes are high and resources constrained.

We also look ahead to the innovations reshaping the industry—AI, cell and gene therapy, and precision medicine—and explore how these technologies will influence strategy, capital allocation, and patient outcomes over the next decade.

Episode Highlights:
A candid leadership journey from bench science to boardroom influence
Practical insights on fundraising, capital strategy, and company scaling
Clear frameworks for navigating clinical and financial uncertainty
What distinguishes high-performing biotech founders and executive teams
A forward-looking perspective on AI and next-generation biopharma innovation

Whether you're a founder, executive, investor, or aspiring biotech leader, this episode offers strategic clarity and actionable guidance for building resilient organizations in a high-risk, high-reward industry. Discover how disciplined leadership, thoughtful capital strategy, and scientific vision come together to shape the future of biopharma.

In this episode of Life Science 360, we sit down with Dr. Dirk Heckel, Chief Technology Officer of Siemens Healthineers, to explore how technology, informatics, and data-driven innovation are redefining modern diagnostics and transforming clinical laboratories worldwide.

Dr. Heckel shares his unique career journey—rooted in both science and technology—and how this dual foundation has shaped his leadership approach in one of healthcare’s most critical domains. From early inspiration to leading large-scale digital transformation initiatives, he reflects on the power of combining deep scientific expertise with advanced digital platforms to build scalable, impactful healthcare solutions.

At the heart of the conversation is the evolving role of the CTO in diagnostics. Dr. Heckel explains how technology strategy must align closely with clinical realities and patient outcomes—ensuring innovation is not just technically sophisticated, but meaningfully integrated into care delivery. He outlines his vision for the modern clinical laboratory: a connected, intelligent, and data-driven ecosystem where systems are interoperable, workflows are optimized, and data flows seamlessly across platforms.

We explore the evolution of lab informatics over the past decade—from siloed, standalone systems to fully integrated digital environments. Dr. Heckel shares real-world examples of how informatics-driven diagnostics enhance accuracy, reduce turnaround times, and improve operational efficiency. The discussion highlights how intelligent automation, interoperability, and advanced analytics are transforming laboratory data into actionable clinical insights.

Importantly, this transformation is not just about efficiency—it is about impact. By turning laboratory information into timely, clinically relevant intelligence, digital platforms can directly influence patient outcomes, enabling earlier diagnoses, more precise treatments, and better overall care.

Episode Highlights:
A compelling leadership journey blending science, informatics, and executive vision
Clear insights into how digital transformation is reshaping modern diagnostics
A deep dive into the evolution of lab informatics—from systems to connected ecosystems
Practical examples of informatics-driven improvements in accuracy and efficiency
A future-forward vision of intelligent, interoperable, and data-driven laboratories

This episode is essential listening for life science leaders, laboratory professionals, informatics experts, and healthcare innovators navigating the rapidly evolving diagnostics landscape—and seeking to understand how technology and clinical excellence converge to shape the future of healthcare.

In this episode, we sit down with Jodi Barrientos, CEO of Ribbon Bio, to explore how innovation infrastructure is shaping the future of synthetic biology—and why scalable DNA manufacturing is critical to unlocking the next generation of biological breakthroughs.

Jodi shares her journey from bench scientist to biotech entrepreneur, reflecting on the pivotal moments that inspired her to build a deep-tech company at the intersection of science, engineering, and advanced manufacturing. She discusses the founding vision behind Ribbon Bio and the mission to overcome longstanding limitations in traditional DNA synthesis technologies.

At the core of the conversation is the challenge of engineering long, complex, high-fidelity DNA constructs—an essential capability for advancing therapeutics, vaccines, agriculture, and industrial biotechnology. Jodi explains how integrating automation, precision engineering, and computational tools enables a new level of scalability and reliability in synthetic DNA production. By combining advanced manufacturing principles with biological design, Ribbon Bio is building the infrastructure needed to accelerate innovation across the life sciences ecosystem.

We also examine the growing role of computational tools and AI in DNA design—how digital modeling and predictive systems can optimize sequence construction, reduce errors, and streamline development cycles. Jodi highlights the commercialization challenges inherent in deep-tech biotech, from capital intensity to long development timelines, and shares leadership lessons learned while building resilient, highly technical teams.

Episode Highlights:
Ribbon Bio’s approach to redefining synthetic DNA manufacturing
Why scalable innovation infrastructure is critical for biotech growth
How precision, automation, and computational tools transform bioengineering
Insights into leading and scaling a deep-tech company
A forward-looking perspective on programmable biology and its impact across industries

This episode offers valuable insights for biotech founders, synthetic biology innovators, investors, and scientist-entrepreneurs seeking to understand how infrastructure, scale, and precision will define the future of programmable biology.

In this episode, we sit down with Suzanne Vyvoda, Founder and CEO of Concordia BioStrategies, to explore how strategic leadership, operational rigor, and collaborative execution form the foundation of successful biotech companies.

Suzanne shares her journey to becoming a founder, CEO, and trusted strategic partner to emerging biotech organizations. She reflects on the philosophy behind Concordia BioStrategies—rooted in alignment, collaboration, and shared purpose—and why early-stage companies must build strong operational frameworks long before a clinical trial begins.

A central theme of the conversation is the evolving role of the Fractional C-Suite leader. Suzanne explains how this model provides growing biotechs with access to senior-level expertise without the overhead of full-time executive hires. In capital-constrained environments, fractional leadership allows companies to move strategically and efficiently—bringing experienced guidance during critical inflection points while preserving runway.

We dive into why operational excellence must start at the earliest stages of company formation. Too often, companies focus heavily on scientific progress while underestimating the infrastructure required to transition into clinical development. Suzanne outlines common operational pitfalls—from misaligned vendors and unclear governance structures to gaps in quality and compliance—and shares practical frameworks for aligning strategy, operations, and execution.

The conversation also emphasizes balance: how companies can move quickly without sacrificing quality, regulatory discipline, or scientific integrity. Early operational decisions, Suzanne notes, directly influence scalability, investor confidence, and ultimately patient impact. Creating alignment between founders, internal teams, CROs, and external partners is not optional—it is essential.

Episode Highlights:
A founder story grounded in collaboration, clarity, and execution
A clear explanation of the Fractional C-Suite model and its strategic value
Practical guidance on operational readiness before entering the clinic
Real-world insights into avoiding costly clinical-stage missteps
A thoughtful framework for balancing speed, quality, and long-term value creation

This episode is essential listening for biotech founders, emerging executives, and investors seeking to understand how disciplined operations, strategic alignment, and experienced leadership can accelerate the journey from discovery to the clinic—while building resilient companies designed for sustainable growth.

In this episode, we explore how San Diego is evolving as a global innovation hub—and what it will take to shape its next chapter at the convergence of AI, DefenseTech, and Life Sciences.

Long recognized for its strengths in biotech and research institutions, San Diego is now entering a new phase defined by cross-sector collaboration and technological convergence. We examine what differentiates the region from other emerging innovation hubs: a unique blend of research excellence, defense infrastructure, entrepreneurial culture, and global connectivity.

The conversation dives into how ecosystems can effectively support both early-stage startups and established industry leaders. As AI reshapes medtech, biotech, and adjacent sectors, the crossover between technology and life sciences is accelerating—unlocking new models of product development, commercialization, and impact. We discuss how founders can leverage this convergence to build more resilient and scalable companies.

We also address the realities entrepreneurs face today: evolving venture funding dynamics, heightened competition for capital, talent acquisition challenges, and the complexity of global expansion. Founders must move beyond pitching ideas to building investable, execution-ready organizations. Capital strategy now demands clarity, differentiation, and disciplined storytelling that resonates with both investors and customers.

A key theme of the episode is “StoryMaking”—the idea that momentum-driven narratives are more powerful than static origin stories. Translating deep science and complex technology into compelling, forward-looking messages is essential for attracting capital, talent, and partnerships. In a crowded global market, narrative clarity can be as important as technical excellence.

We also reflect on leadership within historic organizations navigating reinvention—how to balance legacy and culture with transformation and growth. Mentorship, long-term perspective, and principled decision-making play critical roles in shaping sustainable innovation ecosystems.

Episode Highlights:
A strategic look at San Diego’s next phase as a global innovation hub
Insights into the convergence of AI, DefenseTech, and Life Sciences
Practical guidance on capital strategy and investor readiness
A fresh perspective on StoryMaking as a driver of ecosystem momentum
Actionable advice for global scaling while maintaining focus and resilience
Leadership reflections on legacy, reinvention, and mentorship
Bold predictions on the future of global innovation ecosystems

This episode is essential listening for founders, investors, operators, and ecosystem builders working to shape not only San Diego’s future—but the broader trajectory of global innovation in the decade ahead.